|
|
|
|
Syros Pharmaceuticals Inc (NASDAQ: SYRS) |
|
|
|
| |
Syros Pharmaceuticals Inc 's Working Capital Per Sales
SYRS's Working Capital and Revenue growth
|
Select the Comparisons :
|
|
Select the Ratio:
|
Working Capital Per Revenue▼
|
Working Capital Per Revenue▼
|
| SYRS Working Capital Per Revenue |
(Sep 30 2024)
III. Quarter |
(Jun 30 2024)
II. Quarter |
(Mar 31 2024)
I. Quarter |
(Dec 31 2023)
IV. Quarter |
(Sep 30 2023)
III. Quarter |
| Y / Y Working Capital Change |
-62.24 % |
-51.39 % |
-50.1 % |
-40.04 % |
-55.99 % |
| Y / Y Revenue Change |
- |
- |
- |
- |
-3.32 % |
| Working Capital Per Revenue |
180.32 |
20.35 |
14.38 |
12 |
15.61 |
| Working Capital Per Revenue Ranking |
# |
# |
# |
# |
# |
| Seq. Working Capital Change |
-41.16 % |
-19.36 % |
-30.84 % |
15.06 % |
-24.25 % |
| Seq. Revenue Change |
- |
- |
- |
-89.71 % |
32.79 % |
| Comment on SYRS's Working Capital Per Revenue in the third quarter 2024 |
Syros Pharmaceuticals Inc 's Working Capital Per Revenue sequentially grew to 180.32 during the Q3 2024, above the company average. Due to increase of revenue in the Q3 2024 year on year by -100%.
Within Healthcare sector Syros Pharmaceuticals Inc has achieved the lowest Working Capital Per Revenue. While Working Capital Per Revenue remained unchanged in the Q3 2024 relative to the prior quarter at no. .
|
| Working Capital Per Revenue Ranking |
| Within: |
No. |
| Industry |
# |
| Sector |
# |
| S&P 500 |
# |
| Working Capital Per Revenue Statistics |
| High |
Average |
Low |
0 |
0 |
0 | |
|
|
|
Date modified: 2024-12-29T19:28:16+00:00
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
